BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24621386)

  • 1. Promoter methylation of the RASSF1A gene may contribute to colorectal cancer susceptibility: a meta-analysis of cohort studies.
    Wang HL; Liu P; Zhou PY; Zhang Y
    Ann Hum Genet; 2014 May; 78(3):208-16. PubMed ID: 24621386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant promoter methylation of RASSF1A gene may be correlated with colorectal carcinogenesis: a meta-analysis.
    Wang HL; Zhang Y; Liu P; Zhou PY
    Mol Biol Rep; 2014 Jun; 41(6):3991-9. PubMed ID: 24566684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of RASSF1A promoter methylation in the pathogenesis of hepatocellular carcinoma: a meta-analysis of 21 cohort studies.
    Li YS; Xie Q; Yang DY; Zheng Y
    Mol Biol Rep; 2014 Jun; 41(6):3925-33. PubMed ID: 24566681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of RASSF1A promoter methylation in the pathogenesis of ovarian cancer: a meta-analysis.
    Si JG; Su YY; Han YH; Chen RH
    Genet Test Mol Biomarkers; 2014 Jun; 18(6):394-402. PubMed ID: 24665911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of CDH1 promoter methylation in colorectal carcinogenesis: a meta-analysis.
    Li YX; Lu Y; Li CY; Yuan P; Lin SS
    DNA Cell Biol; 2014 Jul; 33(7):455-62. PubMed ID: 24684676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between RASSF1A promoter methylation and renal cell cancer susceptibility: a meta-analysis.
    Huang YQ; Guan H; Liu CH; Liu DC; Xu B; Jiang L; Lin ZX; Chen M
    Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationships between p16 gene promoter methylation and clinicopathologic features of colorectal cancer: a meta-analysis of 27 cohort studies.
    Chen YZ; Liu D; Zhao YX; Wang HT; Gao Y; Chen Y
    DNA Cell Biol; 2014 Oct; 33(10):729-38. PubMed ID: 24979649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal MGMT promoter methylation may contribute to the risk of esophageal cancer: a meta-analysis of cohort studies.
    Zhao JJ; Li HY; Wang D; Yao H; Sun DW
    Tumour Biol; 2014 Oct; 35(10):10085-93. PubMed ID: 25015189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant promoter methylation of the vimentin gene may contribute to colorectal carcinogenesis: a meta-analysis.
    Li YW; Kong FM; Zhou JP; Dong M
    Tumour Biol; 2014 Jul; 35(7):6783-90. PubMed ID: 24729088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential of RASSF1A promoter methylation as a biomarker for colorectal cancer: Meta-analysis and TCGA analysis.
    Hu F; Chen L; Bi MY; Zheng L; He JX; Huang YZ; Zhang Y; Zhang XL; Guo Q; Luo Y; Tang WR; Sheng MM
    Pathol Res Pract; 2020 Aug; 216(8):153009. PubMed ID: 32703486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant promoter methylation of the SFRP1 gene may contribute to colorectal carcinogenesis: a meta-analysis.
    Chen YZ; Liu D; Zhao YX; Wang HT; Gao Y; Chen Y
    Tumour Biol; 2014 Sep; 35(9):9201-10. PubMed ID: 24929326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma: A meta-analysis and bioinformatics.
    Shao C; Dai W; Li H; Tang W; Jia S; Wu X; Luo Y
    PLoS One; 2017; 12(2):e0171676. PubMed ID: 28207831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic value of RASSF1A hypermethylation in colorectal cancer: a meta-analysis.
    Hu H; Zhou C; Li B; Chen Y; Dai J; Mao Y; Huang T; Yu H; Chen M; Zhao J; Duan S
    Pathol Res Pract; 2018 Oct; 214(10):1572-1578. PubMed ID: 30082160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Methylation status of PCDH10 and RASSF1A gene promoters in colorectal cancer].
    Li M; Yan DG; Liu JL
    Zhonghua Yi Xue Za Zhi; 2016 Feb; 96(6):456-9. PubMed ID: 26875923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter methylation of p16 and RASSF1A genes may contribute to the risk of papillary thyroid cancer: A meta-analysis.
    Jiang JL; Tian GL; Chen SJ; Xu LI; Wang HQ
    Exp Ther Med; 2015 Oct; 10(4):1549-1555. PubMed ID: 26622524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between RASSF1A promoter methylation and thyroid carcinoma: A meta-analysis of 14 articles and a bioinformatics of 2 databases (PRISMA).
    Niu H; Yang J; Yang K; Huang Y
    Medicine (Baltimore); 2017 Nov; 96(46):e8630. PubMed ID: 29145283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of RASSF1A promoter methylation with lung cancer risk: a meta-analysis.
    Huang YZ; Wu W; Wu K; Xu XN; Tang WR
    Asian Pac J Cancer Prev; 2014; 15(23):10325-8. PubMed ID: 25556469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between RASSF1A promoter methylation and NSCLC: a meta-analysis of published data.
    Liu WJ; Tan XH; Guo BP; Ke Q; Sun J; Cen H
    Asian Pac J Cancer Prev; 2013; 14(6):3719-24. PubMed ID: 23886171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between
    Markulin D; Vojta A; Samaržija I; Gamulin M; Bečeheli I; Jukić I; Maglov Č; Zoldoš V; Fučić A
    Cancer Genomics Proteomics; 2017; 14(5):363-372. PubMed ID: 28871003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant promoter methylation of HIN-1 gene may contribute to the pathogenesis of breast cancer: a meta-analysis.
    Dai D; Dong XH; Cheng ST; Zhu G; Guo XL
    Tumour Biol; 2014 Aug; 35(8):8209-16. PubMed ID: 24850174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.